Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of Berzosertib with WBRT in Lung Cancer Brain Metastases
NCT02589522Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of berzosertib in lung cancer and brain metastases, sponsored by National Cancer Institute. Primary endpoint: Dose-limiting Toxicity at 3 weeks. Started May 2017; status: active, not recruiting.
02
Drugs
berzosertib
03
Conditions
lung cancerbrain metastases
Beyond the preview
Go deeper on NCT02589522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589522.